Search

Your search keyword '"Grant, S.W."' showing total 25 results
Start Over Author "Grant, S.W."
25 results on '"Grant, S.W."'

10. What is the impact of providing a transcatheter aortic valve implantation service on conventional aortic valve surgical activity: patient risk factors and outcomes in the first 2-years

Author

Grant, S.W., Devbhandari, M.P., Grayson, A.D., Dimarakis, I., Kadir, I., Saravanan, D.M.T., Levy, R.D., Ray, S.G., and Bridgewater, B.

Subjects
Aortic valve stenosis -- Care and treatment, Aortic valve stenosis -- Patient outcomes, Heart valve replacement -- Usage, Heart valve replacement -- Patient outcomes, Sudden death -- Risk factors, Health
Published
2010

12. A Novel Patient-Specific Model for Predicting Severe Oliguria; Development and Comparison With Kidney Disease: Improving Global Outcomes Acute Kidney Injury Classification

Author

Howitt, S.H., Oakley, J., Caiado, C., Goldstein, M., Malagon, I., McCollum, C., Grant, S.W., Howitt, S.H., Oakley, J., Caiado, C., Goldstein, M., Malagon, I., McCollum, C., and Grant, S.W.

Abstract

Contains fulltext : 229013.pdf (Publisher’s version ) (Closed access), OBJECTIVES: The Kidney Disease: Improving Global Outcomes urine output criteria for acute kidney injury lack specificity for identifying patients at risk of adverse renal outcomes. The objective was to develop a model that analyses hourly urine output values in real time to identify those at risk of developing severe oliguria. DESIGN: This was a retrospective cohort study utilizing prospectively collected data. SETTING: A cardiac ICU in the United Kingdom. PATIENTS: Patients undergoing cardiac surgery between January 2013 and November 2017. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Patients were randomly assigned to development (n = 981) and validation (n = 2,389) datasets. A patient-specific, dynamic Bayesian model was developed to predict future urine output on an hourly basis. Model discrimination and calibration for predicting severe oliguria (< 0.3 mL/kg/hr for 6 hr) occurring within the next 12 hours were tested in the validation dataset at multiple time points. Patients with a high risk of severe oliguria (p > 0.8) were identified and their outcomes were compared with those for low-risk patients and for patients who met the Kidney Disease: Improving Global Outcomes urine output criterion for acute kidney injury. Model discrimination was excellent at all time points (area under the curve > 0.9 for all). Calibration of the model's predictions was also excellent. After adjustment using multivariable logistic regression, patients in the high-risk group were more likely to require renal replacement therapy (odds ratio, 10.4; 95% CI, 5.9-18.1), suffer prolonged hospital stay (odds ratio, 4.4; 95% CI, 3.0-6.4), and die in hospital (odds ratio, 6.4; 95% CI, 2.8-14.0) (p < 0.001 for all). Outcomes for those identified as high risk by the model were significantly worse than for patients who met the Kidney Disease: Improving Global Outcomes urine output criterion. CONCLUSIONS: This novel, patient-specific model identifies patients at increased risk

Published
2020

13. Are Serum Potassium and Magnesium Levels Associated with Atrial Fibrillation After Cardiac Surgery?

Author

Howitt, S.H., Grant, S.W., Campbell, N.G., Malagon, I., McCollum, C., Howitt, S.H., Grant, S.W., Campbell, N.G., Malagon, I., and McCollum, C.

Abstract

Contains fulltext : 229015.pdf (Publisher’s version ) (Closed access), OBJECTIVES: Potassium and magnesium are frequently administered after cardiac surgery to reduce the risk of atrial fibrillation (AF). The evidence for this practice is unclear. This study was designed to evaluate the relationship between serum potassium and magnesium levels and AF after cardiac surgery. DESIGN: Observational cohort study. SETTING: A cardiac intensive care unit in the United Kingdom. PARTICIPANTS: Patients undergoing cardiac surgery between January 2013 and November 2017. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Cardiac rhythm was assessed using continuous electrocardiogram (ECG) monitoring in 3,068 patients on the cardiac intensive care unit. Associations between serum potassium and magnesium concentrations extracted from hospital databases and postoperative AF were assessed using univariable and multivariable analyses. The association between electrolyte supplementation therapy and AF was also analyzed. AF developed within 72 hours of cardiac surgery in 545 (17.8%) of the 3,068 patients. After adjusting for logistic EuroSCORE, surgery type, cardiopulmonary bypass time and age, mean serum potassium concentration <4.5 mmol/L was associated with an increased risk of AF (odds ratio [OR] 1.43 (95% confidence interval (CI): 1.17-1.75), p < 0.001). Mean magnesium concentration <1.0 mmol/L was not associated with an increased risk of AF (OR 0.89, 0.71-1.13, p=0.342), but the administration of magnesium was associated with increased risk of developing AF (OR 1.61, 1.33-1.96, p < 0.001). CONCLUSIONS: Maintaining a serum potassium concentration >/=4.5 mmol/L after cardiac surgery may reduce the incidence of postoperative AF. Magnesium supplementation was associated with an increased risk of postoperative AF. Prospective randomized trials are required to clarify these associations.

Published
2020

14. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF

Author

Lawson, W.E., Grant, S.W., Ambrosini, V., Womble, K.E., Dawson, E.P., Lane, K.B., Markin, C., Renzoni, E., Lympany, P., Thomas, A.Q., Roldan, J., Scott, T.A., Blackwell, T.S., Phillips, J.A., Loyd, J.E., and du Bois, R.M

Subjects
Pulmonary fibrosis -- Causes of, Pulmonary fibrosis -- Research, Pulmonary fibrosis -- Genetic aspects, Protein C -- Research, Gene mutations -- Risk factors, Gene mutations -- Research, Health
Published
2004

15. A Multicentre Observational Study of the Outcomes of Screening Detected Sub-aneurysmal Aortic Dilatation

Author

Wild, J.B., primary, Stather, P.W., additional, Biancari, F., additional, Choke, E.C., additional, Earnshaw, J.J., additional, Grant, S.W., additional, Hafez, H., additional, Holdsworth, R., additional, Juvonen, T., additional, Lindholt, J., additional, McCollum, C., additional, Parvin, S., additional, Sayers, R.D., additional, and Bown, M.J., additional

Published
2013
Full Text
View/download PDF

17. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-[2-Amino-6-(4-morpholinyl)-4-pyrimidinyl]-1H-indazol-3-amine

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

18. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl {(3R,6S)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-3-piperidinyl}carbamate

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

19. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 4-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-N-phenyl-2-morpholinecarboxamide

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

20. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with (2R,5S)-1-[2-Amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-6-methyl-N-phenyl-3-piperidinecarboxamide

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

21. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-{2-Amino-6-[(3R)-3-methyl-4-morpholinyl]-4-pyrimidinyl}-1H-indazol-3-amine

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

22. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 6-(3-Amino-1H-indazol-6-yl)-N4-ethyl-2,4-pyrimidinediamine

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

23. Phosphoinositide-Dependent Kinase-1 (PDK1) kinase domain with 1,1-Dimethylethyl{(3R,5R)-1-[2-amino-6-(3-amino-1H-indazol-6-yl)-4-pyrimidinyl]-5-methyl-3-piperidinyl}carbamate

Author

Medina, J.R., primary, Becker, C.J., additional, Blackledge, C.W., additional, Duquenne, C., additional, Feng, Y., additional, Grant, S.W., additional, Heerding, D., additional, Li, W.H., additional, Miller, W.H., additional, Romeril, S.P., additional, Scherzer, D., additional, Shu, A., additional, Bobko, M.A., additional, Chadderton, A.R., additional, Dumble, M., additional, Gradiner, C.M., additional, Gilbert, S., additional, Liu, Q., additional, Rabindran, S.K., additional, Sudakin, V., additional, Xiang, H., additional, Brady, P.G., additional, Campobasso, N., additional, Ward, P., additional, and Axten, J.M., additional

Published
2011
Full Text
View/download PDF

25. Computational Fluid Dynamics as a Surgical Tool to Optimise the Positioning of the LVAD Outflow Graft for Reducing Aortic Regurgitation.

Author

Lopez-Santana, G.B., De Rosis, A., Grant, S.W., Venkateswaran, R., and Keshmiri, A.

Subjects
*COMPUTATIONAL fluid dynamics, *AORTIC valve insufficiency, *HEART assist devices, *PULSATILE flow, *PATIENT positioning, *BLOOD flow
Abstract

The HeartMate III (HMIII) has improved the survival rate of patients with LVAD to over 50% at five years. Despite this, some patients with continuous flow LVAD develop significant aortic regurgitation (AR) which is associated with adverse outcomes. The optimal surgical positioning of the outflow graft (OG) in the ascending aorta (AA) for minimising the risk of developing AR has not yet been investigated. A 3D aortic model was created using MRI scan data. The 14mm HMIII OG position on the AA was simulated and geometrical parameters including the angle of insertion, the rotational position (right-side and front) and the distance from the aortic valve (AV) were modified. A computational fluid dynamics (CFD) simulation was designed to calculate and obtain the blood velocity, flow perfusion, wall shear stress (WSS) and turbulent kinetic energy (TKE). The pulsatile flow from the LVAD and the native cardiac cycle were used as the inlet boundaries and the Windkessel model was prescribed at the pressure outlets. Based on this CFD simulation, the optimal positioning of the OG for reducing reverse flow, turbulence and WSS around the AV was an angle of 35-55°, attached to the right side of the aorta at 55mm. This angle and distance were also the optional parameters for attaching the OG to the front of the AA. However, the front position resulted in a 2-fold increase in the WSS and higher flow velocity to the carotid arteries. This suggests that the furthest distance possible from the AV without compromising future transplant may help to reduce the risk of developing AR. The position of the OG has potentially significant implications for the blood flow patterns which should be considered during HMIII implantation. Optimized positioning could help to reduce the risk of AR development following LVAD implantation. Further studies are required to validate these simulations in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results